Kolon TissueGene, Inc. (KOSDAQ:950160)

Market Cap	5.20T +45.7%
Revenue (ttm)	5.28B +2.9%
Net Income	-286.63B
EPS	-3,456.66
Shares Out	84.97M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	613,412
Open	60,400
Previous Close	62,100
Day's Range	58,900 - 65,100
52-Week Range	35,800 - 149,000
Beta	-0.56
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Kolon TissueGene

Kolon TissueGene, Inc. develops cell therapies for orthopedic diseases and other unmet medical needs. The company’s lead product is the TG-C that has completed Phase II trials to treat osteoarthritis, as well as rheumatoid arthritis, meniscus, and spinal discs. It is also developing cell therapies for musculoskeletal system disorders, as well as vet medicine. Kolon TissueGene, Inc. was formerly known as TissueGene, Inc. and changed its name to Kolon TissueGene, Inc. in March 2018. The company was founded in 1999 and is headquartered in Rockvill...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 29
• Stock Exchange: KOSDAQ
• Ticker Symbol: 950160

Financial Performance

In 2025, Kolon TissueGene's revenue was 5.16 billion, an increase of 1.68% compared to the previous year's 5.07 billion. Losses were -192.59 billion, 469.8% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 20, 2026

Data Sources Report a data error